![conference banner](/images/conference-banner.jpeg)
摘要
急性髓系白血病患者有异常的、不正常的免疫状态,寻找新的药物靶向途径,为新型靶向药物结合免疫信号,功能并响应铺平了道路。小分子免疫调节药物(IMiDs)是一类来源于母体化合物的药物,沙利度胺。目前有3个小分子免疫调节药物批准用于多种恶性肿瘤:沙利度胺、来那度胺,和新药,pomalidomide。小分子免疫调节药物导致许多免疫生物学效应如细胞因子调节,T细胞共刺激分子的表达下调,共同抑制,增强自然杀伤细胞的活性,调节性T细胞的抑制作用,修复扰动的突触形成T细胞。小分子免疫调节药物已在各种广泛的研究和有前途的临床活动性急性髓系白血病的设置。本文综述了各种小分子免疫调节药物免疫作用,研究各种小分子免疫调节药物急性髓系白血病的理论基础,并发表和正在进行的临床试验调查主要活动在急性髓系白血病。
关键词: 急性髓系白血病,免疫治疗,小分子免疫调节药物,来那度胺,pomalidomide,沙利度胺。
Current Drug Targets
Title:Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)
Volume: 18 Issue: 3
Author(s): Joshua F. Zeidner, Matthew C. Foster.
Affiliation:
关键词: 急性髓系白血病,免疫治疗,小分子免疫调节药物,来那度胺,pomalidomide,沙利度胺。
摘要: AML patients have an aberrant and dysfunctional immune state, paving the way for novel agents targeting pathways that integrate with immune signaling, function, and response. Small molecule immunomodulatory drugs (IMiDs) represent a class of agents derived from the parent compound, thalidomide. There are currently 3 IMiDs approved for a variety of malignancies: thalidomide, lenalidomide, and the newest agent, pomalidomide. IMiDs lead to a multitude of immunobiologic effects such as cytokine modulation, co-stimulation of T cells, down-regulation of co-inhibitory molecules, enhancing natural killer cell activity, inhibition of regulatory T cells, and repairing perturbed synapse formation on T cells. IMiDs have been extensively studied in various AML settings with promising clinical activity. This review discusses the immunologic effects of IMiDs, the rationale for studying IMiDs in AML, and the published and ongoing clinical trials investigating IMiD activity in AML.
Export Options
About this article
Cite this article as:
Joshua F. Zeidner, Matthew C. Foster. , Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML), Current Drug Targets 2017; 18 (3) . https://dx.doi.org/10.2174/1389450116666150304104315
DOI https://dx.doi.org/10.2174/1389450116666150304104315 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
Current Molecular Medicine Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine Pretargeted Radioimmunotherapy with α-Particle Emitting Radionuclides
Current Radiopharmaceuticals P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets Invasive Aspergillosis in Children and Adolescents
Current Pharmaceutical Design Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology Azidothymidine is Effective Against Human Multiple Myeloma: A New Use for an Old Drug?
Anti-Cancer Agents in Medicinal Chemistry Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Nuclear Architecture and Gene Expression in the Quest for Novel Therapeutics
Current Pharmaceutical Design Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
Current Signal Transduction Therapy Nanotechnology and Radiopharmaceuticals: Diagnostic and Therapeutic Approaches
Current Drug Delivery New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia
Current Cancer Drug Targets Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model
Current Drug Targets